Subgroups of patients treated with an aromatase inhibitor (anastrozole) delivered subcutaneously in combination with testosterone
United States of America 
You need to have a Flash player to see the MULTIWEBCAST Viewer. Please click on the link below to download Flash Player.
Get Flash Player
12 slide(s) – English – 2012-03-28
Subgroups of patients treated with an aromatase inhibitor (anastrozole) delivered subcutaneously in combination with testosterone
Testosterone therapy has documented benefits in both men and women’s health. However, increased aromatase activity (age, obesity, medications, breast cancer, etc.) and subsequent elevated estradiol can interfere with testosterone’s effectiveness. In addition, there is increasing evidence of direct adverse affects of estradiol on prostate, breast, uterus, obesity, metabolic syndrome and mood.
We previously determined the dose of subcutaneous anastrozole (aromatase inhibitor), delivered in combination with testosterone as a sustained-release pellet implant, which provided therapeutic levels of testosterone without elevating estradiol.
Data was reviewed in male and female patients treated January-July 2011, to determine the percentage of patients treated with testosterone in combination with anastrozole (testosterone-anastrozole pellet implants) vs. testosterone (implants) alone.
70% of male patients, 95% of breast cancer survivors and 30% of female patients without breast cancer, were treated with anastrozole delivered subcutaneously with testosterone.
Indications for ‘Testosterone-Anastrozole’ therapy in our male patients;
• Elevated estradiol (86%)
• Prostate issues, normal estradiol (8%)
• Other* (6%)
We have uesd ‘Testosterone-Anastrozole’ combination therapy for the following indications;
• Breast cancer
• Increase risk for breast cancer
• Breast discomfort/enlargement, gynecomastia*
• Weight gain, increased abdominal fat/obesity*
• Lack of effect from testosterone
• Anxiety/irritability, PMS, fluid retention/bloating
• Menstrual/migraine headaches
• Gynecologic disorders; endometriosis, fibroids, dysfunctional bleeding
• Insulin resistance, usually with elevated estradiol
1408 insertions of the combination implant were performed July 2009-July 2011.
A significant number of male patients, breast cancer survivors, and females without breast cancer, may benefit from sustained-release, subcutaneous anastrozole delivered in combination with testosterone.
Keywords: Testosterone, aromatase inhibitor, anastrozole, implant, women, men, breast cancer
|
|
